The invention relates to the use of a group of aryl ureas in treating raf mediated diseases and pharmaceutical compositions for use in such therapy of the formula ##STR00001## wherein, Y is NHR Hal is chlorine or bromine, R is H, CH.sub.3 or CH.sub.2OH, and X.sup.1 to X.sup.7 are each, independently, H, OH or --OC(O)C.sub.1-C.sub.4 alkyl, or a salt purified stereoisomer thereof, wherein at least one of X.sup.1 to X.sup.7 is OH or --OC(O)C.sub.1-C.sub.4 alkyl.